Drug Profile

Terbinafine topical - Moberg Pharma AB

Alternative Names: MOB-015; MOB015B; Terbinafine 10%; Terclara; Terclara®

Latest Information Update: 10 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Moberg Derma
Developer Allderma; Moberg Pharma
Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Onychomycosis

Most Recent Events

03 Feb 2025 Launched for Onychomycosis in Norway (Topical)
10 Dec 2024 Terbinafine topical is no longer licensed to Bayer in Europe
08 Aug 2024 Cipher Pharmaceuticals plans to submit regulatory submission for topical terbinafine in Onychomycosis to Health Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com